+377.4%
VT vs GSK
+173.1%
+204.3%
-50.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | 0.0% | -1.9% | +1.9% | +0.9% |
| 7D | +0.4% | -1.8% | +2.3% | +1.3% |
| 30D | +1.0% | -2.2% | +3.1% | +1.9% |
| 3M | +2.4% | -1.8% | +4.2% | +2.6% |
| 6M | +12.0% | -10.6% | +22.6% | +17.1% |
| YTD | +15.3% | +4.4% | +10.9% | +11.0% |
| 1Y | +22.6% | +30.4% | -7.8% | +4.7% |
| 3Y | +74.7% | +60.1% | +14.6% | +28.1% |
| 5Y | +66.1% | +46.8% | +19.4% | +24.2% |
| 10Y | +225.0% | +79.2% | +145.8% | +106.7% |
| All | +377.4% | +173.1% | +204.3% | +105.3% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling